HDL in humans with cardiovascular disease exhibits a proteomic signature. - Wikidata - awgldk - TriplyDB

HDL in humans with cardiovascular disease exhibits a proteomic signature.

HDL in humans with cardiovascular disease exhibits a proteomic signature.

http://www.wikidata.org/entity/Q33544033

about

High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk Proteomics investigations of HDL: challenges and promise Isoforms of apolipoprotein C-I associated with individuals with coronary artery disease.Obesity favors apolipoprotein E- and C-III-containing high density lipoprotein subfractions associated with risk of heart disease Biochemical and functional characterization of charge-defined subfractions of high-density lipoprotein from normal adults.Acute sex steroid withdrawal increases cholesterol efflux capacity and HDL-associated clusterin in men Antisense inhibition of apoB synthesis with mipomersen reduces plasma apoC-III and apoC-III-containing lipoproteins SAA: a link between cholesterol efflux capacity and inflammation?Serum amyloid A in uremic HDL promotes inflammation Testosterone replacement in hypogonadal men alters the HDL proteome but not HDL cholesterol efflux capacity Protective effect of HDL on NADPH oxidase-derived super oxide anion mediates hypoxia-induced cardiomyocyte apoptosis.Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond Proteomic analysis of plasma-purified VLDL, LDL, and HDL fractions from atherosclerotic patients undergoing carotid endarterectomy: identification of serum amyloid A as a potential marker.Discrimination of ischemic and hemorrhagic strokes using a multiplexed, mass spectrometry-based assay for serum apolipoproteins coupled to multi-marker ROC algorithm HDL and cholesterol: life after the divorce?Molecules that mimic apolipoprotein A-I: potential agents for treating atherosclerosis.Glycomic analysis of high density lipoprotein shows a highly sialylated particle.Recent advances in proteomic technologies applied to cardiovascular disease.Biomedical mechanisms of blood stasis syndrome of coronary heart disease by systems biology approaches.Redox regulation of protein damage in plasma.Emerging role of post-translational modifications in chronic kidney disease and cardiovascular disease.Transition from identity to bioactivity-guided proteomics for biomarker discovery with focus on the PF2D platform.Associations of anthropometry and lifestyle factors with HDL subspecies according to apolipoprotein C-III.Mass Spectrometry-Based Proteomic Study Makes High-Density Lipoprotein a Biomarker for Atherosclerotic Vascular Disease.Quantifying HDL proteins by mass spectrometry: how many proteins are there and what are their functions?Elevated serum uric acid in nondiabetic people mark pro-inflammatory state and HDL dysfunction and independently predicts coronary disease.In vivo diagnosis of cervical precancer using Raman spectroscopy and genetic algorithm techniques.Biological Activities, Health Benefits, and Therapeutic Properties of Avenanthramides: From Skin Protection to Prevention and Treatment of Cerebrovascular Diseases

P2860

Q26775420-0E266C31-F74D-4C92-9B37-58421F14CC34 Q27000995-A748B80F-2C87-45F3-A173-861BA47F45D1 Q33780780-29142282-A946-4EBD-8C97-82CD72E9D6AD Q34238727-86DB5F6C-272E-4448-98EE-3BC2D4704EEC Q35028691-83C25024-E467-46DC-BEB3-AFA816959DDC Q35831025-A823B9FB-3E01-4A04-BBD7-D98CCC361B34 Q35839701-E91C440C-DE23-49F8-9C6F-40E725FD0C18 Q35886240-FB286BA0-F302-4A57-9A77-84DA0EB838EC Q35917487-DA880B03-FCB4-4821-A032-01CC3CFF38F7 Q36020300-06EB732B-F40E-4D60-8FF4-C9BE435EC09B Q36406335-6C2783A2-957F-4BB0-BA59-EE5162DB4D00 Q37162996-9B0AB33A-905A-4D91-B327-33B0C37A4C8A Q37456214-D876E775-0E0B-4403-9CA3-7ABD4C2F4FF9 Q37542168-1AF95595-7009-4E8F-BA15-6F1BCA449058 Q37590250-4E7F04D5-4B05-45E5-A535-95D7A53D6A33 Q37671683-B03F2874-470F-454C-A1B4-3EDAFFA6B040 Q37684531-CA68603B-A47B-491F-9DAA-F1D071338780 Q38034137-372CF7AA-13CF-4EFF-B804-D46354847BD6 Q38126853-E49931A7-5A8A-4A1E-B035-B6FD7BEBBBEF Q38195611-2F3E068D-64BC-40C1-98D4-21DA0D8691A8 Q38415749-650B44B0-0380-4B1E-950F-FA31B74D2AAC Q38552059-40679887-0259-4E0F-8637-86B1133C0266 Q40263801-6015428A-5318-45CF-8E57-273AF61D829E Q41908048-09AEBECB-F1A7-42E2-9B1C-2DC579572D96 Q47429427-23429B16-F10C-4D85-A77C-70D2F511432D Q47808087-0D2BE6ED-7B68-466C-AA19-0A1C825AAC27 Q51536959-153598CD-3234-4661-858A-CC534A33D4FC Q58711702-5A170C5E-57CB-4AF5-9B0B-B7796A4ED927

P2860

HDL in humans with cardiovascular disease exhibits a proteomic signature.

http://www.wikidata.org/entity/Q33544033

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

HDL in humans with cardiovascular disease exhibits a proteomic signature.

@ast

HDL in humans with cardiovascular disease exhibits a proteomic signature.

@en

HDL in humans with cardiovascular disease exhibits a proteomic signature.

@nl

type

label

HDL in humans with cardiovascular disease exhibits a proteomic signature.

@ast

HDL in humans with cardiovascular disease exhibits a proteomic signature.

@en

HDL in humans with cardiovascular disease exhibits a proteomic signature.

@nl

prefLabel

HDL in humans with cardiovascular disease exhibits a proteomic signature.

@ast

HDL in humans with cardiovascular disease exhibits a proteomic signature.

@en

HDL in humans with cardiovascular disease exhibits a proteomic signature.

@nl

P1433

Q33544033-4A202BD2-DCB3-4253-BCFA-D38B8E224610

P1476

Q33544033-C78433FA-2BB7-4C88-900E-2D509C4E53D9

P2093

Q33544033-303BB26E-28E0-4A71-AA8D-E374FAAEA996

Q33544033-5FECBFAF-F0DB-4B6D-809F-C5EE84DB8400

Q33544033-6F8245C0-DBCB-45D9-AEE2-FFB4595C9615

Q33544033-721F2089-336D-4E73-82C4-7A9C8F9FF158

Q33544033-72B919F6-A5E3-4971-91DE-B816A4D0C7B6

Q33544033-A85AD4BB-C6E5-492B-9F6B-225D3DEE1D6B

P2860

Q33544033-08D0F659-E4B8-437E-9DD6-A19FC7D9C8D6

Q33544033-180C7B7D-19CE-41FB-88F1-54B975F295E7

Q33544033-19A0B2FC-7834-45DD-B2D4-A4B58774BF54

Q33544033-1FC4E7BF-97F5-47CB-9536-B4C11F6490C6

Q33544033-249606C7-E0D2-4184-B11C-0E83D6EE25D8

Q33544033-262BB0D0-1DCD-466D-906D-8BB6F500383B

Q33544033-29CEA9F4-3E57-4E04-A308-EE93B5724CAA

Q33544033-2C8E044F-A912-4F7D-8152-7DB50F79BB35

Q33544033-2C99AEE9-333D-4DAA-8584-B0232172EBBD

Q33544033-3370BE60-FE4A-4498-AED2-EE56E569DB3B

P304

Q33544033-A084748F-698B-4153-8101-1D43F2183CD8

P31

Q33544033-8767914E-2D31-438A-8062-A029BC0E72F8

P356

Q33544033-909279EA-3506-4828-AA97-781F5FDC6806

P433

Q33544033-0B7226B3-A4A1-4BA4-A74D-EFA5A7EC7F31

P478

Q33544033-B7125634-CF20-48D9-BBFE-E0AB77486EB4

P577

Q33544033-7FBF0FF1-9EC9-462F-91B5-9859F1827916

P5875

Q33544033-49F470D2-D77D-4153-8C74-C37CB8CE9B65

P698

Q33544033-7719716D-B8B5-44CE-BFFD-13AC6F9794CD

P921

Q33544033-06042DB8-EAB1-4028-BFD3-FD72289A7693

P932

Q33544033-9035A350-9F1C-47B2-9248-2BE6542DE532

P356

J.CCA.2010.03.023

P1433

Clinica Chimica Acta

P1476

HDL in humans with cardiovascular disease exhibits a proteomic signature.

@en

P2093

Bryan J Prazen

http://www.w3.org/2001/XMLSchema#string

Erik Nilsson

http://www.w3.org/2001/XMLSchema#string

Philip Mayer

http://www.w3.org/2001/XMLSchema#string

Robert Knopp

http://www.w3.org/2001/XMLSchema#string

Tomás Vaisar

http://www.w3.org/2001/XMLSchema#string

Xue-Qiao Zhao

http://www.w3.org/2001/XMLSchema#string

P2860

Apolipoprotein C-III: understanding an emerging cardiovascular risk factor

Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

Class prediction and discovery using gene microarray and proteomics mass spectroscopy data: curses, caveats, cautions.

Megavariate data analysis of mass spectrometric proteomics data using latent variable projection method.

Complementary use of MALDI and ESI for the HPLC-MS/MS analysis of DNA-binding proteins.

Correcting common errors in identifying cancer-specific serum peptide signatures

Differential exoprotease activities confer tumor-specific serum peptidome patterns

How to distinguish healthy from diseased? Classification strategy for mass spectrometry-based clinical proteomics.

Investigating the quantitative nature of MALDI-TOF MS.

P304

972-979

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CCA.2010.03.023

http://www.w3.org/2001/XMLSchema#string

P433

13-14

http://www.w3.org/2001/XMLSchema#string

P478

411

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42388548

http://www.w3.org/2001/XMLSchema#string

P698

20307520

http://www.w3.org/2001/XMLSchema#string

P921

cardiovascular disease

P932

2862883

http://www.w3.org/2001/XMLSchema#string